2012-Annual Report. Annual Report Institut Pasteur

Size: px
Start display at page:

Download "2012-Annual Report. Annual Report 2012 - Institut Pasteur"

Transcription

1 2012-Annual Report Name of the Department: Name of the Structure: Direction Médicale Pôle Intégré de Recherche Clinique (PIRC) Secondary Affiliation: - Head of the laboratory: Dr Cécile Delval, Personnel: Personnel Cécile Artaud Olivia Chény Isaure de la Croix Margaux Dewitte Annick Dubois Nathalie Jolly Emmanuelle Laffly Hélène Lafolly Camille Pitrou Position Preclinical Clinical study coordinator Secretary Trainee Trainee Preclinical Research Coordinator Five Main publications (in years ): NON APPLICABLE Website address of your laboratory: Key-words of the annual report: Preclinical research Vaccine candidates Gene Therapy Clinical research Regulatory authorities Sponsor Ethic

2 2012-Annual Report I. Presentation The Pôle Intégré de Recherche Clinique (PIRC), created in January 2008: - represents the Institut Pasteur when sponsor, - ensures the coordination of the internal Institut Pasteur Clinical Research Committee (CoRC), - supports scientists for the preparation of clinical research projects before and after submission to the CORC, - is responsible for submission to competent regulatory authorities prior to the beginning of the research, - coordinates the conduct of the research in accordance with the Good Clinical Practices, - ensures all clinical research development steps including budget plan and follow up, - ensures the coordination of the development of the Institut Pasteur vaccine candidates/drugs/gene therapy (preclinical and clinical phases I/II), - ensures a quality assurance system and safety monitoring, - ensures a training course at Institut Pasteur (Recherche sur la Personne et Ethique Appliquée, Research on Human Beings and Applied Ethics, RPEA). II. Activities II. A. Preclinical Research In 2012, the PIRC was involved in two major vaccine development programs (MagTn3, Anthrax), two European FP7 Consortia (STOPENTERICS, ANTIFLU) and one Advanced Therapy project concerning gene therapy for Sanfilippo type B disease. MagTn3: development of a therapeutic anti-cancer vaccine targeting adeno-carcinomaassociated Tn carbohydrate antigen capable of inducing tumor-specific antibodies. Preclinical batches were produced. Toxicology studies and manufacturing of the clinical batches have started and are still on going. Collaboration with C. Leclerc, R. Lo-Man (Unité de Régulation immunitaire et vaccinologie) and S. Bay (Unité de Chimie des biomolécules). Mucopolysaccharidosis (MPS) type III: development of a gene therapy consisting of the intracranial injection of an Adeno-Associated Virus vector coding for the a-n-glucosaminidase, the deficient enzyme in the Sanfilippo type B patient. The PIRC was involved in the coordination of preclinical activities including manufacturing of clinical batches, management of the regulatory toxicology/biodistribution studies, and preparation of all required documentation for clinical trial authorization submission. Collaboration with J.-M. Heard (Département de Neuroscience). Anthrax: development of a therapeutic vaccine for the army force in case of high-risk exposure. The manufacturing of the FIS and rpa development batches and the analytical method development by the subcontractor in charge of the vaccine candidate manufacturing have started and are still on going. Collaboration with P. Goossens (Laboratoire Pathogénie des toxi-infections bactériennes). STOPENTERICS FP7 Consortium: development of a novel prophylactic vaccine against Shigella. As the PIRC is involved as sponsor representative of the phase I clinical trial, the PIRC has participated in the annual consortium meeting. The PIRC was also involved in the coordination of preclinical activities including manufacturing of the starting material for the preclinical and clinical batches of the vaccine candidate. Collaboration with P. Sansonetti, FP7 coordinator, and A. Phalipon (Unité de Pathogénie microbienne moléculaire) and L. Mulard (Unité de Chimie des biomolécules). ANTIFLU FP7 Consortium: development of new and alternative drugs against influenza by exploiting the crucial function of host cell determinants as targets of small molecules and RNAi inhibitors, so-called indirect antiviral targets, in order to prevent viral infection and growth. The PIRC has participated in the annual consortium meeting and will be involved in the coordination of the preclinical activities. Collaboration with M. Lecuit (Groupe à 5 ans Microorganismes et barrières de l'hôte) and T. Meyer (the Max Planck Institute for Infection Biology, FP7 Coordinator).

3 II.B. The clinical research activities The role of the PIRC is to ensure the representation of Institut Pasteur when sponsor. Its duty is to bridge laboratory-based research with patient-oriented clinical research. Scope of activities of the PIRC: Clinical research = any research involving human beings: biological samples and/or personal data and/or physiopathology and/or epidemiology, and/or clinical trials In 2012: 186 projects were piloted by the PIRC since new clinical research projects were reviewed by the Clinical Research Committee (CoRC) according to regulatory, legal and ethical compliance. The Institut Pasteur was sponsor/legal responsible for 29/46 projects (63%) of these projects. 11/46 projects (24%) were conducted in collaboration with Institut Pasteur International Network. Repartition of Institut Pasteur sponsorship of research projects (n=178) Major studies piloted by the PIRC, completed in 2011 (IP sponsor): BCG & bladder cancer: Objective: to analyze predictive factors for success of BCG therapy in bladder cancer. Collaboration with M. Albert (Centre d Immunologie Humaine). RMV HIV: Objective: to test a HIV vaccine based on a recombinant Measles vaccine vector. This Phase I clinical trial is an open-label, single-centre dose-escalation study on healthy subjects. Results were analyzed and study report was completed. Publication is in progress and publically registered on Belgian Competent Authorities data base. Collaboration with F. Tangy (Unité de Génomique virale et vaccination).

4 Major studies piloted by the PIRC (IP sponsor), still in progress: Chronovac: Objective: to evaluate immune response of the administration of 2 vaccines against yellow fever and measles in young children. Start of volunteers recruitment in February 2011; current status (Dec. 2012) : 97 included/124 planned. Collaboration with C. Goujon (Centre Médical de l Institut Pasteur, clinical investigator) and M.-L. Gougeon (Unité de Recherche et d Expertise Immunité anti-virale). METHS: Objective: to identify causes of Verneuil disease. Collaboration with A. Nassif (Centre Médical de l Institut Pasteur, clinical investigator) and O. Joint-Lambert (Laboratoire de Microbiologie, Hôpital Necker, Paris). Start of volunteers recruitment in November 2011 ; current status (Dec. 2012) : 35 included/75 planned. LabEx Milieu Intérieur Genetic & Environmental Determinants Of Immune Phenotype Variance: Establishing A Path Towards Personalized Medicine : Objective: constitution of a large healthy volunteers cohort to define the determinants of human immune variance. Start of volunteers recruitment in September 2012; current status (Dec. 2012): 261 included/1000 planned. Collaboration with M. Albert (Centre d'immunologie Humaine) and L. Quintana-Murci (Unité Génétique évolutive humaine). INECOC: Objective: to detect and characterize the presence of infectious agent transcripts in oncology. Start of volunteers recruitment in February 2012; current status (Dec. 2012): 15 included/100 planned). Collaboration with A. Gessain (Unité d'epidémiologie et physiopathologie des virus oncogènes). EVOIMMUNOPOP: Objective: to characterize the genetic architecture of populations with different ethnic backgrounds. Start of volunteers recruitment in December 2012 ; current status (Dec. 2012) : 31 included/400 planned. Collaboration with L. Quintana-Murci (Unité Génétique évolutive humaine). II.C. European Ethical Process In 2012, the PIRC was fully involved in the preparation of Applications for EU Grant in order to support scientists in the implementation of the Regulatory & Ethical considerations. II.D. PIRC as a regulatory-ethical referent The PIRC was solicited to contribute to the implementation of the non-opposition procedures for collections of human biological samples stored by the CNRs. In order to support scientists in their publication, the PIRC has deeply reviewed the guidelines of the International Committee of Medical Journal Editors (ICMJE) and implemented specific recommendations for scientists. II.E. Teaching / communication Bimonthly workshops Ateliers du PIRC Objective: to clarify scientific, regulatory and ethic aspects of the clinical research environment. Started in 2010, this initiative was largely successful and was renewed in Training Course «Recherche sur la Personne et Ethique Appliquée / Research on Human Beings and Applied Ethics» (RPEA) Objective: to clarify the rules of the research on human beings with a particular focus on ethics. For the fourth consecutive year, this course has trained students with previous experience in clinical research to the regulatory aspects of research on the person.

5 Training Course «Clinical Research in the Institut Pasteur International Network ( CREPIN ) In 2012, PIRC has been requested by the International Division to build up a new course on Clinical Research dedicated to the International Network. The first session will teach students from Asia; it will take place in Cambodia in April PIRC web site In 2012, the PIRC set up a new web site

Vaccines Researches for the Future:

Vaccines Researches for the Future: ITMO Microbiologie et maladies infectieuses Vaccines Researches for the Future: The corevac initiative Pr Brigitte AUTRAN Institute Infection-Cancer-Immunity, UPMC, Paris Pr Jean François Delfraissy Institute

More information

AERES report on the research unit

AERES report on the research unit Section des Unités de recherche AERES report on the research unit Génomique, bioinformatique et applications From the Conservatoire National des Arts et Métiers (CNAM) Mai 2010 Section des Unités de recherche

More information

Report from the visiting commitee

Report from the visiting commitee Section des Unités de recherche Report from the visiting commitee Research unit: Biothérapies hépatiques University of Nantes January 2008 Section des Unités de recherche Report from the visiting committee

More information

ACCESS TO THE SEASONAL FLU VACCINE IN CANADA. How the flu shot makes its way from the laboratory to the doctor s office.

ACCESS TO THE SEASONAL FLU VACCINE IN CANADA. How the flu shot makes its way from the laboratory to the doctor s office. ACCESS TO THE SEASONAL FLU VACCINE IN CANADA How the flu shot makes its way from the laboratory to the doctor s office. Health Canada is the federal department responsible for helping Canadians maintain

More information

HCERES report on research unit:

HCERES report on research unit: Research units HCERES report on research unit: Actions for oncogenesis understanding and Target Identification in ONcology ACTION Under the supervision of the following institutions and research bodies:

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000

More information

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works. November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also

More information

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction

More information

Moving an HIV Vaccine from Lab to Clinic: The Importance of Industry Engagement

Moving an HIV Vaccine from Lab to Clinic: The Importance of Industry Engagement Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) Annual Meeting 2013: Moving an HIV Vaccine from Lab to Clinic: The Importance of Industry Engagement Executive

More information

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit?

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? ELLEN PURÉ, Ph.D. Issues Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? Can the academic review process support individual career development in

More information

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

exactly. The need for efficiency in developing effective new therapeutics has never been greater. exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,

More information

Teaching department: Epidemiology and Public Health. Pasteur/CNAM School of Public Health

Teaching department: Epidemiology and Public Health. Pasteur/CNAM School of Public Health Teaching department: Epidemiology and Public Health Pasteur/CNAM School of Public Health PROGRAM OF THE VACCINOLOGY COURSE (3 rd - 28 th March, 2014) Directors of the course Armelle PHALIPON Molecular

More information

FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE

FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration

More information

HCERES report on research unit:

HCERES report on research unit: Research units HCERES report on research unit: Translational Gene Therapy for neuromuscular and retinal diseases Under the supervision of the following institutions and research bodies: Université de Nantes

More information

ATIP Avenir Program 2014. Applicant s guide

ATIP Avenir Program 2014. Applicant s guide ATIP Avenir Program 2014 Applicant s guide Important dates: - November 29 th 2013: deadline for the online submission, the mailing of the hard copy of the scientific project, and the letters of recommendation

More information

Ph.D. in Molecular Medicine

Ph.D. in Molecular Medicine Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to

More information

SMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS

SMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2015-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, AND ADMINISTRATION

More information

Report from the visiting committee

Report from the visiting committee Section des Unités de recherche Report from the visiting committee Research unit : Cancer Virotherapy UMR_S 701 University Louis Pasteur - Strasbourg 1 February 2008 Section des Unités de recherche Report

More information

Clinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission

Clinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission Clinical trials: The EU perspective Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission Content 1.EU: The global picture 2.EU & Clinial trials: The

More information

Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015

Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient

More information

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) 7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 44 credit hours: 1- Compulsory courses: 14 credit hours. 1504801, 1504802, 1504803,

More information

«I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie

«I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie «I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie I-Reivac Pr Odile Launay Inserm, Université Paris Descartes, AP-HP, Hôpital Cochin, Paris F-CRIN, une infrastructure pour l

More information

FACULTY OF MEDICAL SCIENCE

FACULTY OF MEDICAL SCIENCE Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research

More information

Editorial. Yves Levy, Executive Director

Editorial. Yves Levy, Executive Director Editorial Yves Levy, Executive Director I am delighted to announce the creation of a new research centre: the Vaccine Research Institute (VRI). The VRI addresses the unprecedented challenge of developing

More information

Valentina Gualato, Ph.D. Process Development Scientist

Valentina Gualato, Ph.D. Process Development Scientist COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing

More information

From Research Services and Process Development to GMP Manufacturing

From Research Services and Process Development to GMP Manufacturing From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development

More information

Immunity Unit Test Z

Immunity Unit Test Z Immunity Unit Test Z Name MB Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Which of the pathogens in Figure 31.1 cause disease by taking over healthy

More information

TRACKS INFECTIOUS DISEASE EPIDEMIOLOGY

TRACKS INFECTIOUS DISEASE EPIDEMIOLOGY Dr. Shruti Mehta, Director The development of antibiotics, improved access to safe food, clean water, sewage disposal and vaccines has led to dramatic progress in controlling infectious diseases. Despite

More information

THE LINCOLN INSTITUTE OF HEALTH

THE LINCOLN INSTITUTE OF HEALTH THE LINCOLN INSTITUTE OF HEALTH Background The Chair in the Care of the Older Person will be part of the new Lincoln Institute of Health, a cross disciplinary research collaboration linking schools, colleges

More information

Obtaining Funding in Clinical Research

Obtaining Funding in Clinical Research Obtaining Funding in Clinical Research Ellen Seely, MD Director of Clinical Research Endocrinology, Diabetes and Hypertension Division Vice Chair, Faculty Development, Department of Medicine Brigham and

More information

JIANGSU CARTMAY INDUSTRIAL CO.,LTD www.labfurniture.asia mail: info@labfurniture.asia

JIANGSU CARTMAY INDUSTRIAL CO.,LTD www.labfurniture.asia mail: info@labfurniture.asia The basic layout, the main functions and instrumentation concept of micro Inspection Division laboratory, 1, Virology Laboratory 1. Functions: for the city to monitor the prevalence of HIV disease, dealing

More information

EMA and Progressive Multifocal Leukoencephalopathy.

EMA and Progressive Multifocal Leukoencephalopathy. EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of

More information

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates

More information

Career Opportunities within the French Alliance for Life and Health Sciences

Career Opportunities within the French Alliance for Life and Health Sciences 1 Career Opportunities within the French Alliance for Life and Health Sciences Mireille Guyader, PhD Director, Inserm-USA Office INSERM KEY FIGURES (Year 2013) Budget: 970 M (~ $1.2 Billion) Human resources:

More information

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis

CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society

More information

Chapter 3. Immunity and how vaccines work

Chapter 3. Immunity and how vaccines work Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Corporate Presentation June 2, 2015

Corporate Presentation June 2, 2015 Corporate Presentation June 2, 2015 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these

More information

GUIDELINES for BIH translational Ph.D. grants

GUIDELINES for BIH translational Ph.D. grants GUIDELINES for BIH translational Ph.D. grants The BIH aims at training a new generation of translational scientists and will establish different interlinked training programs. This includes funding of

More information

Call 2014: High throughput screening of therapeutic molecules and rare diseases

Call 2014: High throughput screening of therapeutic molecules and rare diseases Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for

More information

Noam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il

Noam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il Noam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il Experience CEO at N. Danenberg Holding (2000) Ltd) 2000 - Present (13 years) Investment Consulting Firm Consultant at Bonzai Holding Ltd.

More information

Fee-for-service cores for Investigational New Drug enabling studies

Fee-for-service cores for Investigational New Drug enabling studies UC DAVIS INSTITUTE FOR REGENERATIVE CURES Fee-for-service cores for Investigational New Drug enabling studies Pipeline pathway at UC Davis Institute for Regenerative Cures Basic Research Proof of Concept

More information

Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective

Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food

More information

Biochemistry. Entrance Requirements. Requirements for Honours Programs. 148 Bishop s University 2015/2016

Biochemistry. Entrance Requirements. Requirements for Honours Programs. 148 Bishop s University 2015/2016 148 Bishop s University 2015/2016 Biochemistry The Biochemistry program at Bishop s is coordinated through an interdisciplinary committee of chemists, biochemists and biologists, providing students with

More information

BACKGROUNDER NEW GRANTS TO ACCELERATE HIV VACCINE DEVELOPMENT

BACKGROUNDER NEW GRANTS TO ACCELERATE HIV VACCINE DEVELOPMENT BACKGROUNDER NEW GRANTS TO ACCELERATE HIV VACCINE DEVELOPMENT The Bill & Melinda Gates Foundation has provided 16 grants totaling $287 million over five years to establish an international network of HIV

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or

More information

Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles

Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Neurosciences, sciences cognitives, neurologie, psychiatrie Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Technologie pour la santé 1 NEUROSCIENCE MEDICAL CHALLENGES

More information

National Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be

National Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s National Cancer Institute

More information

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Biology of Cancer and Infection BCI

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Biology of Cancer and Infection BCI Research units HCERES report on research unit: Biology of Cancer and Infection BCI Under the supervision of the following institutions and research bodies: Université Joseph Fourier - Grenoble - UJF Institut

More information

Chikungunya: An emerging outbreak from East Africa to Indian Ocean, 2004-2007

Chikungunya: An emerging outbreak from East Africa to Indian Ocean, 2004-2007 Chikungunya: An emerging outbreak from East Africa to Indian Ocean, 2004-2007 A. Flahault, G. Aumont, V Boisson, X de Lamballerie, F. Favier, B.A. Gaüzère, D. Fontenille, S. Journeaux, V. Lotteau, C. Paupy,

More information

ADMEDUS ANNOUNCES FURTHER DATA FROM HERPES SIMPLEX VACCINE TRIAL

ADMEDUS ANNOUNCES FURTHER DATA FROM HERPES SIMPLEX VACCINE TRIAL ADMEDUS Ltd ABN 35 088 221 078 REGISTERED OFFICE: Level 1, 197 Adelaide Terrace Perth Western Australia 6000 PO Box 6879 East Perth Western Australia 6892 ASX ANNOUNCEMENT T +61 (0)8 9266 0100 F +61 (0)8

More information

Journée des Industriels du Réseau TRIGGERSEP

Journée des Industriels du Réseau TRIGGERSEP Journée des Industriels du Réseau TRIGGERSEP Djillali ANNANE Hôpital Raymond Poincaré (AP-HP) Lab Cell Death Inflamation & Infection UMR1173 UVSQ/INSERM Mercredi 3 juin 2015 Institut Pasteur Paris Expertise:

More information

DEPARTMENT OF HEALTH AND HUMAN SERVICES. Health Resources and Services Administration. Advisory Council on Blood Stem Cell Transplantation

DEPARTMENT OF HEALTH AND HUMAN SERVICES. Health Resources and Services Administration. Advisory Council on Blood Stem Cell Transplantation This document is scheduled to be published in the Federal Register on 01/21/2016 and available online at http://federalregister.gov/a/2016-01127, and on FDsys.gov Billing Code 4165-15 DEPARTMENT OF HEALTH

More information

The Immune System and Disease

The Immune System and Disease Chapter 40 The Immune System and Disease Section 40 1 Infectious Disease (pages 1029 1033) This section describes the causes of disease and explains how infectious diseases are transmitted Introduction

More information

Manufacturing process of biologics

Manufacturing process of biologics Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:

More information

Name: Understanding Viruses. HIV, Herpes, Influenza, small pox, chicken pox, measles, mumps, bird flu, swine flu.

Name: Understanding Viruses. HIV, Herpes, Influenza, small pox, chicken pox, measles, mumps, bird flu, swine flu. Name: Understanding Viruses Section 1 1. List as many viruses as you can. HIV, Herpes, Influenza, small pox, chicken pox, measles, mumps, bird flu, swine flu. 2. How do viruses reproduce? (aside from the

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

Clinical Trials. In Singapore. Clinical Trials in Asia Pacifi c. Introduction. Healthcare Clusters. www.asiabiotech.com

Clinical Trials. In Singapore. Clinical Trials in Asia Pacifi c. Introduction. Healthcare Clusters. www.asiabiotech.com Clinical Trials In Singapore Dr Say-Beng Tan, Dr Eugene Fidelis Soh, and Dr Han-Chong Toh Introduction Clinical trials are the gold standard for the evaluation of new treatment strategies. New treatments

More information

Cancer Clinical Trials: In-Depth Information

Cancer Clinical Trials: In-Depth Information Cancer Clinical Trials: In-Depth Information The Drug Development and Approval Process 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3)

More information

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Department of immunology

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Department of immunology Research units HCERES report on research unit: Department of immunology Under the supervision of the following institutions and research bodies: Institut Pasteur Paris Institut National de la Santé Et

More information

Template for essential information to be provided for proposals including clinical trials / studies / investigations

Template for essential information to be provided for proposals including clinical trials / studies / investigations Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous

More information

Master of Science in Biomedical Sciences

Master of Science in Biomedical Sciences Master of Science in Biomedical Sciences Faculty of Medicine Good health is our greatest treasure. Understanding the human body, healthy and diseased, is the stepping stone to finding tools to improving

More information

ATIP Avenir Program 2016 Young group leader. Applicant s guide

ATIP Avenir Program 2016 Young group leader. Applicant s guide ATIP Avenir Program 2016 Young group leader Applicant s guide Important dates - November 26 th 2015: deadline for the online submission, the mailing of the hard copy of the scientific project, and the

More information

Therapeutic Goods Administration Orphan Drugs Program: Discussion paper

Therapeutic Goods Administration Orphan Drugs Program: Discussion paper Therapeutic Goods Administration Orphan Drugs Program: Discussion paper Submission from the Clinical Oncology Society of Australia and Cancer Council Australia March 2015 The Clinical Oncology Society

More information

Regulatory Issues in Genetic Testing and Targeted Drug Development

Regulatory Issues in Genetic Testing and Targeted Drug Development Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006 Genetic and Genomic Tests are Types

More information

Recruiting Emerging Leaders in Oncology

Recruiting Emerging Leaders in Oncology ARC Foundation Call for proposals 2016 Recruiting Emerging Leaders in Oncology Letter of intent submission deadline: July 8 th, 2015 1. Background and Objectives To heighten France's competitiveness and

More information

Health of Women (HoW) Program Launch: Participant Workbook

Health of Women (HoW) Program Launch: Participant Workbook Health of Women (HoW) Program Launch: Participant Workbook June 24-25, 2013 Name: Title: Affiliation /Organization: Email: Workbook completion instructions: Record your action-oriented ideas throughout

More information

GUIDELINE. Vaccination of Health Care Workers. Version 2 December 2012. Centre for Healthcare Related Infection Surveillance and Prevention

GUIDELINE. Vaccination of Health Care Workers. Version 2 December 2012. Centre for Healthcare Related Infection Surveillance and Prevention GUIDELINE Vaccination of Health Care Workers Version 2 December 2012 Centre for Healthcare Related Infection Surveillance and Prevention Introduction This guideline provides information to support Hospital

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information

Vaccines Research & Development. Exhibitor

Vaccines Research & Development. Exhibitor International Conference on Vaccines Research & Development Nov 2015 02-04 Baltimore USA Bronze Sponsor Exhibitor Bronze Sponsor : United Scientific Group Welcome Message United Scientific Group takes

More information

The Role of the Patient/Consumer in Establishing a Dynamic Clinical Research Continuum:

The Role of the Patient/Consumer in Establishing a Dynamic Clinical Research Continuum: The National Working Group on Evidence-Based Health Care The Role of the Patient/Consumer in Establishing a Dynamic Clinical Research Continuum: Models of Patient/Consumer Inclusion August 2008 The Working

More information

Immunity and how vaccines work

Immunity and how vaccines work 1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms

More information

CAREERS IN BIOMEDICAL SCIENCE & THE IBMS. Betty Kyle Scottish Regional Representative IBMS Lead Biomedical Scientist NHS Lanarkshire

CAREERS IN BIOMEDICAL SCIENCE & THE IBMS. Betty Kyle Scottish Regional Representative IBMS Lead Biomedical Scientist NHS Lanarkshire CAREERS IN BIOMEDICAL SCIENCE & THE IBMS Betty Kyle Scottish Regional Representative IBMS Lead Biomedical Scientist NHS Lanarkshire What is a biomedical scientist? Biomedical scientists carry out investigations

More information

Catalent Biologics & Clinical Supplies The SMART Solution

Catalent Biologics & Clinical Supplies The SMART Solution Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany

More information

VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH

VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH Lucia Faccio, Direttore Sviluppo Ricerca Fondazione Telethon Why should academia transfer

More information

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:

More information

Working with ICH Quality Guidelines - the Canadian Perspective

Working with ICH Quality Guidelines - the Canadian Perspective Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction

More information

M110.726 The Nucleus M110.727 The Cytoskeleton M340.703 Cell Structure and Dynamics

M110.726 The Nucleus M110.727 The Cytoskeleton M340.703 Cell Structure and Dynamics of Biochemistry and Molecular Biology 1. Master the knowledge base of current biochemistry, molecular biology, and cellular physiology Describe current knowledge in metabolic transformations conducted

More information

Introduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)

Introduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act) Overview of the Healthcare Policy Introduction For Japan, which is becoming an ultra-aging society ahead of other countries, it is important to realize the world s most advanced medical technologies and

More information

ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES

ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Specialized Master of Science in Experimental Biomedical Research

Specialized Master of Science in Experimental Biomedical Research Curriculum for the award of the Degree of Specialized Master of Science in Experimental Biomedical Research options: Neuroscience Infection, Inflammation and Cancer Cardiovascular and Metabolic Health

More information

STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005

STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005 STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005 VerDate 14-DEC-2004 06:53 Jan 05, 2006 Jkt 039139 PO 00000 Frm 00001 Fmt 6579 Sfmt 6579 E:\PUBLAW\PUBL129.109 APPS10 PsN: PUBL129 119 STAT. 2550 PUBLIC LAW

More information

A leader in the development and application of information technology to prevent and treat disease.

A leader in the development and application of information technology to prevent and treat disease. A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

More information

Chapter 21. What Are HIV and AIDS?

Chapter 21. What Are HIV and AIDS? Section 1 HIV and AIDS Today What Are HIV and AIDS? Human immunodeficiency virus (HIV) is the virus that primarily affects cells of the immune system and that causes AIDS. Acquired immune deficiency syndrome

More information

Multiple Choice Questions

Multiple Choice Questions C hapter 13 WHY DO WE FALL ILL Multiple Choice Questions 1. Which one of the following is not a viral disease? (a) Dengue (b) AIDS (c) Typhoid (d) Influenza 2. Which one of the following is not a bacterial

More information

J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S

J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S PURPOSE JDRF, the world s leading non-profit organization with

More information

Sciences du Médicament / Pharmaceutical Science

Sciences du Médicament / Pharmaceutical Science Sciences du Médicament / Pharmaceutical Science Vous trouverez ici les conditions de candidature pour les différentes voies de M2 de la mention «Sciences du Médicament / Pharmaceutical Science». Certaines

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies

More information

FACULTY OF MEDICAL SCIENCE

FACULTY OF MEDICAL SCIENCE Doctor of Philosophy in Biochemistry FACULTY OF MEDICAL SCIENCE Naresuan University 73 Doctor of Philosophy in Biochemistry The Biochemistry Department at Naresuan University is a leader in lower northern

More information

The University of Texas Health Science Center at San Antonio Tobacco Funds Budget Fiscal Year Ending August 31, 2015

The University of Texas Health Science Center at San Antonio Tobacco Funds Budget Fiscal Year Ending August 31, 2015 Permanent Health Funds for Higher Education (Fund 810) Permanent Health Funds will be assigned to schools to support health education, research programs, and infrastructure operations. Strategy F.1.2.,

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY

More information

A Genetic Analysis of Rheumatoid Arthritis

A Genetic Analysis of Rheumatoid Arthritis A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

Drug Safety of Stem Cells and other Novel Therapeutics

Drug Safety of Stem Cells and other Novel Therapeutics Course 1.2 Drug Safety of Stem Cells and other Novel Therapeutics 13 17 October 2014 MRC Centre for Drug Safety Science Institute of Translational Medicine University of Liverpool, Liverpool, UK European

More information

1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:

1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1: Full-fledged work is in progress towards construction and cloning of codon optimized envelope with subsequent aims towards immunization of mice to study immune responses. 1 2 4 5 6 Figure 4.1: Gel picture

More information